Lupin Limited has informed the Exchange regarding a press release dated October 24, 2025, titled "Lupin Launches Authorized Generic Version of Ravicti® in the United States".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has announced the launch of an authorized generic version of Ravicti® (glycerol phenylbutyrate) in the US market. Ravicti® is an FDA-approved drug used for the long-term management of urea cycle disorders (UCDs), a rare genetic condition. An authorized generic is typically launched with the consent of the brand owner, often allowing the company to capture additional market share in the segment. This adds to Lupin's growing portfolio of complex generics and specialty products in the United States.
This launch strengthens Lupin's US generics business and expands its footprint in the rare disease segment. It could contribute to US revenue growth over time, though the immediate financial impact is likely modest given the niche nature of the drug.